The activation peptide cleft exposed by thrombin cleavage of FXIII-A2 contains a recognition site for the fibrinogen α chain

Blood

Volumn 121, Issue 11, 2013, Pages 2117-2126

  Smith, Kerrie A ^a   Pease, Richard J ^a   Avery, Craig A ^b   Brown, Jane M ^a   Adamson, Penelope J ^a   Cooke, Esther J ^a   Neergaard Petersen, Søs ^a,c   Cordell, Paul A ^a   Ariëns, Robert A S ^a   Fishwick, Colin W G ^b   Philippou, Helen ^a   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13 A2; BLOOD CLOTTING FACTOR 13A; FIBRIN; FIBRIN ALPHA CHAIN; FIBRIN GAMMA CHAIN; FIBRINOGEN; FIBRINOGEN ALPHA CHAIN; GLUTAMINE; LYSINE; PENTYLAMINE; POLYLYSINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SYNTHETIC PEPTIDE; THROMBIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 13; FACTOR XIII SUBUNIT A; FIBRINOGEN ALPHAC; ISOPROTEIN; PEPTIDE FRAGMENT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; FEMALE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; CRICETULUS; ENZYME ACTIVE SITE; GENETICS; HAMSTER; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN QUATERNARY STRUCTURE;

ANIMALS; CATALYTIC DOMAIN; CHO CELLS; CRICETINAE; CRICETULUS; FACTOR XIII; FIBRINOGEN; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, QUATERNARY; THROMBIN;

MLCS; MLOWN;

EID: 84877625984     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-446393     Document Type: Article

References (40)

1. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest. 1983;71(5):1336-1341.
2. Ashcroft AE, Grant PJ, Ariëns RA. A study of human coagulation factor XIII A-subunit by electrospray ionisation mass spectrometry. Rapid Commun Mass Spectrom. 2000;14(17): 1607-1611.
3. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94(5):271-305.
4. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem. 1973;248(4):1395-1407.
5. Takagi T, Doolittle RF. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry. 1974;13(4):750-756.
6. Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thromb Haemost. 2007;97(6):890-898.
7. Lorand L, Gray AJ, Brown K, et al. Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. Biochem Biophys Res Commun. 1974;56(4):914-922.
8. Curtis CG, Brown KL, Credo RB, et al. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 1974;13(18):3774-3780.
9. Hornyak TJ, Shafer JA. Role of calcium ion in the generation of factor XIII activity. Biochemistry. 1991;30(25):6175-6182.
10. Credo RB, Curtis CG, Lorand L. Ca2+-related regulatory function of fibrinogen. Proc Natl Acad Sci USA. 1978;75(9):4234-4237.
11. Credo RB, Curtis CG, Lorand L. Alpha-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects. Biochemistry. 1981; 20(13):3770-3778.
12. Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann N Y Acad Sci. 1983;408:28-43.
13. Blombäck B, Hessel B, Hogg D. Disulfide bridges in nh2 -terminal part of human fibrinogen. Thromb Res. 1976;8(5):639-658.
14. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70:247-299.
15. Lewis SD, Shields PP, Shafer JA. Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin. J Biol Chem. 1985;260(18):10192-10199.
16. Ruf W, Bender A, Lane DA, Preissner KT, Selmayr E, Müller-Berghaus G. Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: influence of inhibitors of fibrin polymerization. Biochim Biophys Acta. 1988; 965(2-3):169-175.
17. Chen R, Doolittle RF. γ-γ Cross-linking sites in human and bovine fibrin. Biochemistry. 1971; 10(24):4486-4491.
18. Matsuka YV, Medved LV, Migliorini MM, Ingham KC. Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. Biochemistry. 1996;35(18):5810-5816.
19. Helms CC, Ariëns RA, Uitte de Willige S, Standeven KF, Guthold M. a-a Cross-links increase fibrin fiber elasticity and stiffness. Biophys J. 2012;102(1):168-175.
20. Ritchie H, Lawrie LC, Crombie PW, Mosesson MW, Booth NA. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen). J Biol Chem. 2000;275(32): 24915-24920.
21. Bale MD, Westrick LG, Mosher DF. Incorporation of thrombospondin into fibrin clots. J Biol Chem. 1985;260(12):7502-7508.
22. Hada M, Kato M, Ikematsu S, Fujimaki M, Fukutake K. Possible cross-linking of factor VIII related antigen to fibrin by factor XIII in delayed coagulation process. Thromb Res. 1982;25(1-2): 163-168.
23. Mosher DF, Johnson RB. Specificity of fibronectin—fibrin cross-linking. Ann N Y Acad Sci. 1983;408:583-594.
24. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69(1): 209-216.
25. Wiman B, Collen D. On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. J Biol Chem. 1979;254(18):9291-9297.
26. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest. 1980;65(2):290-297.
27. 2-antiplasmin cross-linking. Blood. 2011;117(23):6371-6374.
28. Smith KA, Adamson PJ, Pease RJ, et al. Interactions between factor XIII and the alphaC region of fibrinogen. Blood. 2011;117(12): 3460-3468.
29. Takebe M, Soe G, Kohno I, Sugo T, Matsuda M. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost. 1995;73(4): 662-667.
30. Lord ST, Binnie CG, Hettasch JM, Strickland E. Purification and characterization of recombinant human fibrinogen. Blood Coagul Fibrinolysis. 1993;4(1):55-59.
31. Binnie CG, Hettasch JM, Strickland E, Lord ST. Characterization of purified recombinant fibrinogen: partial phosphorylation of fibrinopeptide A. Biochemistry. 1993;32(1):107-113.
32. Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006; 49(5):1071-1080.
33. Weiss MS, Metzner HJ, Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett. 1998;423(3):291-296.
34. Pinkas DM, Strop P, Brunger AT, Khosia C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007;5(12):e327.
35. Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost. 2011;9(1):9-20.
36. Tsurupa G, Tsonev L, Medved L. Structural organization of the fibrin(ogen) alpha C-domain. Biochemistry. 2002;41(20): 6449-6459.
37. Matacić S, Loewy AG. The identification of isopeptide crosslinks in insoluble fibrin. Biochem Biophys Res Commun. 1968;30(4): 356-362.
38. Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci USA. 1994;91(15):7296-7300.
39. Loewy AG, Dunathan K, Gallant JA, Gardner B. Fibrinase III. Some enzymatic properties. J Biol Chem. 1961;236:2644-2647.
40. Schrode J, Folk JE. Stereochemical aspects of amine substrate attachment to acyl intermediates of transglutaminases. Human blood plasma enzyme (activated coagulation factor XIII) and guinea pig liver enzyme. J Biol Chem. 1979; 254(3):653-661.